Setting scientifically justified sampling time points is a critical step in in vitro release testing (IVRT) and dissolution studies, ensuring that release profiles are fully characterized, discriminating, and acceptable to regulatory authorities. This article explains the principles, sample types, testing items, methodology, and practical considerations for designing sampling point schemes for oral, transdermal, semisolid, and parenteral modified-release dosage forms in accordance with pharmacopoeial standards and ICH quality guidelines.
Technical Overview
In vitro release testing evaluates the rate and extent at which the active pharmaceutical ingredient (API) is released from a dosage form under standardized conditions. The experimental design of sampling time points—often referred to as the sampling point setting experiment—determines when aliquots of the dissolution or release medium are withdrawn during the test so that a complete, reproducible, and discriminating release profile can be constructed.
The selection of sampling points is not arbitrary. Regulatory and pharmacopoeial frameworks, including USP General Chapters <711> (Dissolution), <724> (Drug Release), <1724> (Semisolid Drug Products—Performance Tests), the Chinese Pharmacopoeia (ChP 0931), and guidance documents from major health authorities, require that time points be justified by formulation behavior, intended clinical performance, and the purpose of the study. Poorly placed time points can mask dose dumping, fail to distinguish between formulations, or undermine the development of an in vitro–in vivo correlation (IVIVC).
A well-designed sampling scheme typically captures three characteristic regions of the release curve for modified-release products: an early point demonstrating that the initial release fraction is controlled (commonly 20–30% released), a middle point characterizing the release rate (approximately 50%), and a final point demonstrating essentially complete release (80–85% or more). For in vivo relevance, alignment with quality target product profile (QTPP) attributes and absorption kinetics is essential under the quality-by-design (QbD) paradigm described in ICH Q8(R2), Q9(R1), and Q14.
Testing Samples
Oral Extended-Release Solid Dosage Forms
Matrix and reservoir tablets, multiparticulate pellets, and extended-release capsules containing hydrophilic polymers, insoluble matrices, or membrane-controlled coatings. These products require multi-point profiles spanning several hours to fully characterize the controlled-release mechanism.
Delayed-Release (Enteric-Coated) Products
Enteric-coated tablets, pellets, and capsules that must withstand gastric fluid and release drug in intestinal fluid. Sampling design involves a two-stage test: an acid stage followed by a buffer stage with closely spaced early points.
Immediate-Release Solid Dosage Forms
Conventional tablets and capsules for which single-point (Q criterion) or two-point specifications are set during method development, particularly for biowaiver and BCS-based applications where early discrimination is required.
Transdermal Delivery Systems
Drug-in-adhesive, matrix, and reservoir patches evaluated with vertical diffusion cells or the paddle-over-disk apparatus, requiring sampling intervals over six or more hours to characterize sustained percutaneous release.
Semisolid Dosage Forms
Creams, gels, and ointments assessed by in vitro release testing using synthetic membranes in vertical diffusion cells, where slope-based release rates are derived from multiple time points over a defined exposure period.
Parenteral Depot Systems
Microspheres, liposomes, and implants that release drug over days to months, studied with flow-through cells or sample-and-separate techniques under real-time and accelerated conditions.
Testing Items
The sampling point setting experiment generates and evaluates the following data elements:
- Cumulative percentage of drug released at each predetermined time point, corrected for sampling losses or media replacement
- Complete release profile curves (mean ± SD, %RSD) for 6 to 12 dosage units per batch
- Fit to release kinetic models, including zero-order, first-order, Higuchi, Korsmeyer–Peppas, and Weibull functions
- Discriminating power assessment, comparing profiles of intentionally varied formulations using the difference factor (f1) and similarity factor (f2)
- Proposed acceptance criteria for each time point, including staged testing (L1/L2/L3) with defined Q values and allowable variability
- Analytical supporting data: filter and membrane adsorption checks, drug stability in media at test temperature, and validated assay performance per ICH Q2(R2)
Testing Methods
Apparatus and Conditions
Apparatus selection follows the dosage form and the relevant pharmacopoeial chapter: USP Apparatus 1 (basket) or 2 (paddle) for oral solids, Apparatus 3 (reciprocating cylinder) for extended-release multiparticulates, Apparatus 4 (flow-through cell) for poorly soluble drugs and depot systems, Apparatus 5 (paddle over disk) and 7 (reciprocating holder) for transdermal systems, and vertical diffusion cells for semisolids. Media volume, pH, ionic strength, surfactant level, hydrodynamics (rotation speed or flow rate), and temperature—typically 32 °C for dermal systems and 37 ± 0.5 °C for oral and parenteral systems—are established to maintain sink conditions (dose not exceeding one-third of saturation solubility).
Design of the Sampling Schedule
Sampling points are placed according to the release rate class of the product:
- Immediate release: a single Q point (for example, NLT 80% released in 30–45 minutes) or two points for rapidly dissolving products, with an early point at 5–15 minutes to detect overly fast release
- Delayed release: acid stage at 2 hours with no more than 10% released, followed by buffer-stage points at approximately 10, 20, 30, 45, and 60 minutes
- Extended release: at least three points—an early point where 20–30% is released (dose-dumping check), a midpoint near 50%, and a final point at 80–85% or greater to demonstrate complete release
- Transdermal and semisolid systems: intervals such as 0.5, 1, 2, 4, 6, and 8 hours, with a minimum of five points for slope determination by linear regression of cumulative release versus the square root of time
- Long-acting depots: initial burst assessment within the first 24 hours followed by scheduled sampling over days or weeks, supplemented by accelerated conditions at elevated temperature and pH
Experimental Procedure
Dosage units are introduced into pre-equilibrated media; at each time point, a defined aliquot is withdrawn from a standardized position midway between the media surface and the top of the stirring element, at a fixed distance from the vessel wall. Samples are filtered immediately through validated low-adsorption filters, with discarded initial volumes documented, and analyzed by a validated UV or HPLC method. Withdrawn volume is either replaced with fresh equilibrated media or accounted for by volume correction calculations. Manual sampling procedures must be qualified against automated systems to control timing drift.
Data Evaluation and Point Refinement
Profiles from the preliminary screen are used to refine point placement: points are added where the release curve changes slope, and redundant points in plateau regions are removed. For comparative studies using the similarity factor f2, at least three time points are required, only one measurement after 85% release is included, and the %RSD of early points must satisfy the established criteria. The discriminating capability of the final scheme is confirmed by demonstrating that profiles of formulations with intentionally altered critical material attributes or process parameters are statistically distinguishable.
Applications
Sampling point setting experiments support a broad range of pharmaceutical development and quality activities:
- Formulation screening and optimization within a QbD framework, linking critical quality attributes to release performance
- Establishment of release or dissolution specifications for regulatory submissions
- Development of Level A, B, and C in vitro–in vivo correlations to support biowaivers and clinical relevance justification
- Comparability exercises for generic products, demonstrating profile similarity to the reference listed drug
- Post-approval change assessments (composition, site, scale, and process changes) using profile comparison
- Routine quality control release testing and stability programs, detecting release-rate drift over the shelf life
- Support for in vitro release testing performed in accredited third-party laboratories, national pharmacopoeial laboratories, and in-house QC facilities
FAQ
Why are at least three sampling points required for extended-release products?
Multiple points are necessary to characterize the shape of the release curve. The early point guards against dose dumping, the middle point defines the sustained-release rate that governes in vivo exposure, and the final point demonstrates that the drug is essentially completely released, supporting both safety and efficacy assessment.
How are sampling points positioned if the release curve is unknown at the start?
An exploratory study with dense, evenly spaced points (for example, every 30 minutes over 12 hours) is performed first. The resulting profile is then used to select meaningful specification points and to remove redundant points from the routine method.
Should the withdrawn sample volume be replaced?
Yes, in most single-vessel designs the volume is replaced with fresh medium at test temperature, or a mathematical correction for cumulative dilution is applied. The chosen approach must be consistent across the study and documented in the method.
How is the discriminating power of the chosen time points demonstrated?
Profiles of formulations with deliberate changes in critical variables—such as polymer grade, coating level, or compression force—are compared with the target profile. If the method detects these differences through f2 or statistical testing at the selected points, the sampling scheme is considered discriminating.
What happens if more than 85% release occurs at an early time point?
For f2 similarity calculations, only one measurement after 85% release should be used, because the plateau region contributes little discriminatory information. The final specification point is then set at or near the time when release first exceeds 85%.
Are sampling point requirements different for transdermal and semisolid products?
Yes. For these products, sampling points serve to establish a linear release rate over the test duration, typically by regression of cumulative release against the square root of time, following the performance-testing principles of the relevant pharmacopoeial chapter for semisolid drug products.